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Steroids are potent inhibitors of inflammation and wound 
repair. Local administration of steroids directly into the larynx 
has been reported in many laryngeal diseases. Aim: The 
purpose of this study is to review related literature about the 
use of steroid injection in patients with benign, inflammatory 
and chronic vocal disease. Methodology: We performed an 
electronic survey in Medline database and selected clinical 
trials regarding steroid use in benign laryngeal diseases. 
Results: Steroids are indicated in these situations: 1) acute 
inflammatory diseases, mainly when edema compromises the 
airways; 2) auto- immune disease with laryngeal involvement; 
3) laryngeal stenosis; 4) benign lesions of the vocal folds, 
e.g., nodules, polyps and Reinke’s edema, to reduce the 
inflammatory reactions before phonosurgery or in an attempt 
to avoid surgery; 5) In phonosurgery, aiming to reduce 
scarring. In this case, it could be used as a preventive measure 
in vocal fold scarring, or for scar treatment. Conclusion: 
Steroids may be considered an important therapeutic 
option in the management of many diseases, specially the 
inflammatory ones, associated with vocal changes. 
Keywords: vocal fold scarring, steroids, steroid injection, 
inflammatory lesions of vocal fold, laryngeal disease.
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INTRODUCTION
Steroids are molecules synthesized by our bodies 
to regulate a vast number of physiological, immune, and 
metabolic processes. Steroids are broadly used due to 
their anti-inflammatory and immunomodulation properties. 
They have a unique, essentially genomic (transcriptional) 
mode of action characterized by the activation (transac-
tivation) or inhibition (transrepression) of numerous tar-
get genes. These molecules act upon a number of cells, 
involving innate (macrophages, granulocytes, mast cells) 
and adaptive (lymphocytes) immune responses, apart 
from other cells (fibroblasts, epithelial and endothelial 
cells). Steroid anti-inflammatory effectiveness is related 
to the inhibition of a number of cytokines, enzymes, and 
inflammation mediators and to the induction of cytokines 
and anti-inflammatory molecules such as lipocortin, res-
ponsible for inhibiting the release of vasoactive substances 
and chemotactic agents. Lipolytic and proteolytic enzymes 
are also reduced through lysosomal stabilization, as well as 
the overflow of leukocytes to sites of injury. Lymphocyte 
counts and degree of fibrosis are modified. All such steps 
will clearly affect the elements and stages of inflammatory 
response.1,2 (Figure 1)
Steroids inhibit multiple sites of the immune sys-
tem. They interfere with both humoral and cell immune 
response. Research findings suggest their effect in immune 
disease is more related to blocking inflammatory response 
than inhibiting immune response.2
Synthetic steroidal drugs differ from each other in 
how strong their glucocorticoid is, and are thus dosed to 
provide for equal potency. They have different levels of 
mineralocorticoid activity and are categorized as a function 
of effect duration. (Figure 2)
The glucocorticoid equivalence table considers 
systemic drug administration (intramuscular, intravenous, 
or subcutaneous). It is important to stress the difference 
between plasmatic and biologic half-life. The first refers 
to blood hormone levels, while the latter to the time for 
which the drug will be available in tissue; glucocorticoid 
tissue presence will determine the duration of its thera-
peutic effect. Such duration varies depending on the salt 
used in the formulation of the glucocorticoid. When pre-
pared with salts that form freely soluble ester (mono and 
disodium phosphate, sodium succinate), glucocorticoids 
are promptly taken in. On the other hand, if the steroid is 
prepared with other salts that form less soluble byproducts 
(acetate, dipropionate, acetonide, diacetate, and hexace-
tonide) uptake is slower.3
Glucocorticoids are the most effective anti-inflam-
matory agent available, as they offer symptom alleviation 
in a series of clinical manifestations. They, however, pose a 
potential risk for adverse side effects in a number of organs 
depending on dosage and treatment duration. When used 
for short periods of time (up to two weeks), even at high 
dosages, the probability of adverse side effects occurring 
is low. In prolonged therapy severe side effects set in, 
thus reducing their effectiveness in addressing chronic 
diseases.2
Local steroid injections have been used as a means 
of rationalizing the use of this medication. This mode of 
administration allows for high local drug concentration 
with lower risk of systemic adverse side effect.
Steroids are mostly indicated to treat acute inflam-
matory diseases involving the larynx, mainly in situations 
where edema may compromise the airways. Some studies 
have shown steroids being used in various chronic diseases 
that introduce laryngeal lesions and voice alteration.
This study aims to perform a literature review on the 
use of steroid injections on the vocal folds of patients with 
benign, inflammatory, or chronic laryngeal disease.
Cell Affected Element Induced Response
Macrophages and 
monocytes
Arachidonic acid and byproducts (prostaglandins and 
leukotrienes)
Reduced vasodilatation, vascular patency, nociceptor 
hypersensitivity, immune response
Cytokines (interleukin-1 and -6, TNF-α) Reduced T-cell and fibroblast activation
 
Endothelial cells
ELAM-1 and ICAM-1 Reduced leukocyte adhesion
Cytokines (interleukin -1) Same as above
Arachidonic acid byproducts Same as above
Basophiles Histamine; leukotriene C4 IgE inhibition
Fibroblasts Arachidonic acid byproducts Proliferation inhibition
Lymphocytes
Cytokines (IL-1, IL-2, IL-3, IL-6, TNF-α, GM-CSF, interfe-
ron gamma)
Same as above
Figure 1. Sites and modes of action of glucocorticoids in inflammatory and immune responses.*
* Adapted from reference 2..
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MATERIALS AND METHOD
A non-systematic search was performed on the 
MEDLINE database (from January of 1960 to November 
of 2006) to find medical papers reporting on the use of 
steroids in benign vocal fold disease.
The search for papers on Medline was done using 
keywords corticosteroids, steroid injection, vocal folds and 
laryngeal alone and in combination.
Other papers were also included besides the ones 
obtained from the above mentioned search.
LITERATURE REVIEW
The use of steroid on managing laryngeal disease is 
well established, particularly in handling conditions such 
as epiglottitis, croup, and laryngeal edema.4-6
Steroids are potent inhibitors of inflammation and 
healing.
The most common administration modes are oral, 
intramuscular, and intravenous. Local steroid administra-
tion in the larynx has been reported for various laryngeal 
diseases.
Krespi7 reported on the use of steroid injections in 
the lesions of six patients with laryngeal sarcoidosis.
Patients with systemic lupus erythematosus and 
Wegener’s granulomatosis with laryngeal involvement 
present, in most of the cases, improvement in symptoms 
with steroid injections done directly on the laryngeal 
lesions.8,9
Success has been achieved in the treatment of 
patients with laryngeal stenosis with injections of triamci-
nolone on the site of stenosis.10,11
Some authors have reported on the use of steroid 
injections on the vocal folds to treat local inflammatory 
benign diseases such as nodules, polyps, and Reinke’s 
edema, in an attempt to avoid surgery.
In 1967, Yanagihara12 reported good results af-
ter injecting dexamethasone on vocal folds assisted by 
indirect laryngoscopy in patients with nodules. This 
technique is however quite inaccurate, thus hampering 
its reproducibility. Tateya et al.13 developed a technique 
using a fibroscope and a curved needle introduced orally 
to inject triamcinolone under local anesthesia on vocal 
fold nodules. Twenty-three of the 27 patients enrolled in 
this study had nodules associated with vocal abuse and 
occupational stress (20 were teachers). Endoscopic findings 
showed that vocal fold nodules disappeared in 17 of the 
27 subjects and were reduced in size in 10 patients after 
injection. Maximum phonation time was of 10.9s before 
the procedure and moved up to 13.9s afterwards, showing 
a significant increase (p<0.05). Remission or improvements 
in dysphonia were seen in 96% of the cases. There was 
no recurrence of adverse side effects such as reduction 
on vocal fold size or muscle atrophy.
These same authors14 conducted a study using this 
same technique to inject triamcinolone on Reinke’s space 
of the vocal folds of 44 patients with moderate Reinke’s 
edema. Remission and improvements were observed in 
almost all patients as far as dysphonia is concerned (as-
sessed by patients) and in vocal fold endoscopic findings. 
The mean maximum phonation time increased significantly 
from 9s to 11.4s after the procedure (p<0.01). In female 
patients, pitch also increased significantly from 168Hz to 
181Hz (p<0.05) after steroid injection.
Surgical technique and instrumentation used to 
remove benign vocal fold lesions and yet preserve maxi-
mum amounts of normal adjacent tissue have improved 
along the years. Understanding the body-cover vocal fold 
model is fundamental for any surgical approach. A mucosal 
wave is generated as the mucosal lining slides over the 
vocal ligament and the vocal muscle. This cover can be 
divided into layers with different mechanical properties, 
Drug
Anti-inflammatory 
strength*
Dose equivalent (mg)
Relative sodium 
retention**
Plasmatic half-life 
(minutes)
Biologic half-life 
(hours)
Hydrocortisone 1 20 1 90 8 - 12
Cortisone 0.8 25 0.8 30 8 - 12
Prednisone 4 5 0.2 60 12 - 36
Prednisolone 5 4 0 180 12 - 36
Methylprednisolone 5 4 0 180 12 - 36
Triamcinolone 5 4 0 300 12 - 36
Betamethasone 25 0.5 0 100 - 300 24 - 72
Dexamethasone 25 0.75 0 100 - 300 24 - 72
Figure 2. Glucocorticoid equivalence for systemic administration.
* Glucocorticoid effect
** Mineralocorticoid effect
Adapted from reference 3.
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and may be differentiated by the concentration of collagen 
and elastin fibers. Most benign lesions take place in the 
superficial layer of the lamina propria, and surgical appro-
aches should ideally be confined to this layer. Violation 
of the deeper layers of the lamina propria and the vocal 
ligament is associated with scar tissue formation. Such scar 
leads to the fixation of the mucosal cover to deep tissues, 
thus hampering the formation of the mucosal wave and 
causing dysphonia. Vocal fold scars are the most common 
cause of post-surgery dysphonia (35%).15
Steroids have been clinically used in vocal fold 
surgery to reduce scar tissue formation; they may also be 
used preventively or therapeutically against scar tissue.
Bouchayer and Cornut16 reported on the use of 
hydrocortisone injections on the vocal folds at the end of 
microsurgery to remove benign lesions such as nodules, 
manly when sings of inflammation, cysts, sulcus, and 
bridges are present. When treating iatrogenic scars, hydro-
cortisone is injected on the vocal fold, an incision is made 
in the superior surface of the vocal fold, and a microflap 
is raised separating it from the vocal ligament, without 
however removing any type of tissue. The authors reported 
improvements on vocal fold malleability, glottic closure, 
and voice quality. Courey et al.17 have also described the 
use of steroids under the microflap after benign lesion 
removal so as to reduce scar tissue formation consequent 
to the microflap.
Mortensen and Woo18 injected methylprednisolone 
on the vocal folds of 12 patients with post-surgery iatroge-
nic fibrosis assisted by indirect laryngoscopy under local 
anesthesia. Significant improvements were observed on 
voice quality, as measured by the GRABS scale (p<0.01). 
In stroboscopic examination improvements were seen on 
vibration amplitude (p<0.05) and mucosal wave (p<0.05). 
This study also looked at 18 patients with vocal folder 
nodules or polyps and 4 patients with sarcoidosis or gra-
nuloma. Eleven of the 18 patients with nodules or polyps 
had significant improvement and did not require surgery. 
One patient with sarcoidosis was able to avoid repeated 
general anesthesia procedures with steroid injection. Two 
patients with contact granuloma improved with steroid in-
jections and did not require surgery. One patient required 
surgery and pathology test results showed vocal fold tu-
berculosis. Twenty-eight (82%) of the 34 patients improved 
their statuses. The authors reported that on-lesion steroid 
injections have three main indications: 
1) reduce granulation tissue and promote primary 
healing; 
2) reduce hypertrophic scar formation; and 
3) reduce inflammation to avoid surgery.
The use of steroid injection to prevent vocal fold 
fibrosis is based only on theory, as there are no clinical 
or histological studies presenting consistent findings on 
the effect of steroids in vocal fold healing.
The only published study that histologically and 
functionally analyzes the effect of vocal fold steroid 
injection was produced by Coleman et al.19 in 1999. A 
microflap lateral to the vocal folds of 15 dogs was raised 
and triamcinolone was injected on one of the vocal folds; 
the other was left for control purposes. After 2, 4 and 6 
weeks respectively groups of five dogs were slaughtered 
and vocal fold histological studies were done to analyze 
inflammatory infiltrate and neovascularization. Paired 
tests showed increased presence of inflammatory infiltrate 
around the microflap of vocal folds treated with steroids for 
2, 4 and 6 weeks (p<0.2). Neovascularization in vocal folds 
treated with steroids was reduced in 2 weeks (p<0.005), 
but greater in 4 and 6 weeks (p<0.005). A time-dependent 
normal distribution curve was produced based on histolo-
gical data to better characterize the effect of steroids upon 
the healing process. Steroid-treated tissues had responses 
delayed by 12 days for inflammatory infiltrate and 21 for 
vasculogenesis. Videostroboscopy was done preoperati-
vely and the day the dogs were slaughtered to allow for 
a functional qualitative and quantitative analysis. No sig-
nificant differences were found in appearance, amplitude, 
mucosal wave, or malleability between the two vocal folds. 
In this study, although the healing process was delayed by 
steroids, the parameters assessed during videostroboscopy 
did not show differences between treated and control vocal 
folds after 2, 4 and 6 weeks.
Scars are generally related to fibrous tissue. Studies 
have shown that increases in collagen - especially type 1 
collagen - promote fibrosis, and that collagen content has 
direct impact on scar strength.20 In the case of vocal fold 
fibrosis, dense collagen deposits have also been found in 
the injured lamina propria of animal model vocal folds21-23. 
However, recent research suggests that other components 
of the extracellular matrix such as hyaluronic acid, fibro-
nectin, and decorin may also affect fibrous tissue. Although 
collagen is the main molecule, it is not the only one to 
determine tissue viscoelastic properties.24
A study on the role of monocytes/macrophages in 
healing, subcutaneous deposit hydrocortisone at 0.6mg/g 
of bodily weight was given to pigs to induce long term 
monocytopenia. Macrophage level in the wound was 
reduced to 1/3 in relation to control subjects. Fibroblasts 
would normally appear within three days, but were not 
seen before 5 days and their proliferation was reduced 
on the healing site.25
Injections of deposit steroids such as triamcinolone 
have been used in hypertrophic scars and cheloid. Carroll 
et al.26 showed in vitro that collagen and cell proliferation 
reduction promoted by triamcinolone is mediated by al-
terations in cytokine secretion.
A study is currently being conducted in animal mo-
dels at our service to histologically assess whether steroids 
can be used in the formation stages of the extracellular 
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matrix components as an alternative to reduce vocal fold 
mucosal stiffness introduced by postoperative healing. 
Twelve rabbits were used in this study. All subjects got 
dexamethasone injections through a lateral microflap rai-
sed in one of their vocal folds, while the other vocal fold 
was left with the microflap untreated for control purposes. 
Histology tests were done to assess inflammatory infiltrate 
and amount of collagen after three and seven days, during 
acute inflammatory response. In terms of inflammatory 
infiltrate, there was no difference in the number of cells 
around the microflap. Amounts of collagen, however, 
were significantly lower in the steroid-treated vocal fold 
after three days, and this difference was sustained after 
seven days. 27
DISCUSSION
Steroids are broadly employed in various laryngeal 
diseases, mainly because of their powerful anti-inflamma-
tory properties. Alongside benefits are, however, various 
potential adverse side effects that may involve a series of 
tissues depending on dosage and treatment duration. Any 
agent can be administered in systemic acute conditions, 
as undesired side effects are not observed.
When the therapeutic goal involves reaching higher 
concentrations in one single target - e.g.: larynx - local 
steroid injection is effective and introduces fewer systemic 
side effects, as long as dosage is strictly observed and 
treatment is short term. Longer half-life steroids such as 
triamcinolone, methylprednisolone acetate, and dexame-
thasone are preferably used in local injections. Triamcino-
lone is broadly used in joint injections in the orthopedic 
practice28,29, with confirmed effectiveness and safety. 
Bouchayer and Cornut16 used vocal fold hydrocortisone 
injections to reduce present signs of inflammation, but 
probably due to shorter medication half-life the impact on 
healing was limited. In theory, longer half-life steroids do 
a better job of preventing fibrous tissue formation.
The main adverse effect of this treatment mode is 
muscle and gland atrophy. None of the papers referred to 
in this study reported such event. However, Mortensen and 
Woo18 suggest patients with fibrosis should have intervals 
of 6 to 12 weeks between injections and those suffering 
from inflammatory lesions should either have one single 
injection or more in longer intervals.
Many autoimmune diseases such as systemic lupus 
erythematosus, Wegener’s granulomatosis, and sarcoidosis 
may present laryngeal lesions that cause dysphonia and 
respiratory involvement. Most symptoms are resolved 
with steroid therapy, usually employed for longer periods 
of time. Immunosuppressant drugs and chemotherapy 
medication (azathioprine, cyclophosphamide, and me-
thotrexate) are also associated to reduce or stop steroid 
administration. However, patients with severe laryngeal 
involvement have improved when taking local steroid 
injections, possibly an alternative with fewer adverse side 
effects.
Healing modulation is the biggest factor in the suc-
cess of stenosis surgical treatments. Steroids were tested 
with this purpose, but their use remains controversial30. On 
the one hand, they act on collagen formation and degra-
dation, reducing granulation tissue formation, as observed 
by Gnanapragasam10 and Rosen and Vered11. On the other 
hand, they interfere with the migration of epithelial cells 
and on the healing of developing ulcers, which may get 
infected and increase the chances of restenosis. Local 
steroid injection may also produce cartilage resorption.31 
Mitomycin-C has shown more promising results than ste-
roids to treat laryngeal stenosis.32
Acquired benign laryngeal lesions affecting the vo-
cal folds are the consequence of inflammatory processes 
that stem basically from three factors: vocal fold abuse 
or poor use of the voice (trauma), irritative processes 
(smoking, pharyngeal-laryngeal reflux, pollution etc), and 
individual predisposing factors.33
Vocal fold nodule disease is characterized by the 
distension of capillaries and venules, mild perivascular 
hemorrhage, tissue fibrin migration, diffuse edema, and 
fibrosis. Polyps, Reinke’s edema, and contact granuloma 
also have inflammatory traits. Thus, local steroid injections 
are a rational and particularly effective means to treat 
these lesions in their early stages, before fibrous tissue 
has developed.13,33
Vocal fold fibrosis is caused by injury and inflam-
mation. Inadequate surgical technique can easily introduce 
fibrous scars on the vocal folds. These scars disorganize 
the vocal fold mucosal lamina propria and change the 
biomechanical properties of the vocal folds, as mucosal 
viscoelastic strength is increased. This, in turn, reduces 
vocal fold vibration and causes dysphonia, a condition 
difficult to be treated.24
No treatment method can yet be considered effec-
tive in resolving vocal fold fibrosis.24 Steroid injections are 
among the most broadly employed treatments and have 
been associated with reduced rigidity, improved glottal 
closure, and good resulting voice quality, as observed 
by Bouchayer and Cornut16 and Mortensen and Woo18. 
Nonetheless, some degree of fibrosis always remains in 
place. Many other substances have been attempted, such 
as bovine collagen34, autologous collagen35, and autologous 
fat36 to enhance vocal fold flexibility. However, none of 
these materials is able to restore the changes introduced 
in the lamina propria by fibrosis and repair viscoelasticity 
to levels identical to those found in normal vocal folds.
As the treatment options for vocal fold fibrosis are 
limited, studies have been conducted to prevent fibrosis 
formation. Many surgeons are using steroid injections on 
surgical wounds to enhance injury healing. Steroids affect 
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collagen synthesis and maturation, change wound tensile 
strength, inhibit fibroblast function, and suppress defense 
cell antibacterial and phagocytic properties, resulting in 
modified patterns and delayed wound healing37. The effect 
is more visible within the first four days of treatment. Aside 
from inhibiting normal infection resistance, after four days 
steroids have almost imperceptible effect38. According to 
Branski et al.39, the acute stage of the healing process is 
critical. Therapeutic interventions introduced at this time 
may reduce vocal fold scar stiffness, as inflammatory 
cells and fibroblasts start synthesizing extracellular ma-
trix components two or three days after injury. If fibrosis 
prevention is the goal, the right time to use long half-life 
steroids is at the onset of the inflammatory process, i.e., 
at the end of surgery.
The alterations introduced by steroids in collagen 
synthesis were reported by Campagnolo e Tsuji27, but they 
are associated only with the acute inflammatory stages. 
Coleman et al.19 followed their patients for 6 weeks and 
found no difference in vocal fold vibration under func-
tional stroboscopic assessment. Histological examination 
did not consider matrix components (collagen, elastin etc) 
and consequently their association with vocal fold mucosa 
vibration; they looked only at inflammatory infiltrate and 
neovascularization. In spite of the proven effect of steroi-
ds in healing, more studies are required mainly to assess 
whether collagen changes persist in the long run.
Reports on the use of mitomycin-C have not shown 
benefit in preventing fibrosis.40 Encouraging results were 
recently reported from liver cell growth factor injections, 
as a potent anti-fibrotic agent.41 Ideal prevention and 
treatment modes for vocal fold fibrosis are yet to be es-
tablished.
CONCLUSION
Systemic steroids are recommended to treat acute 
laryngeal inflammation. In chronic inflammatory disease, 
steroids may be used systemically or injected locally on 
the lesion in more severe cases.
Local steroid injections are advantageous as they 
allow higher drug concentrations on the target with redu-
ced potential for adverse systemic side effects. They may be 
indicated to 1) reduce edema, benign mucosal lesion, and 
granuloma size before surgery or as an attempt to avoid 
it, and 2) minimize post-surgery iatrogenic scar. Although 
many authors reported on local steroid injection at the 
end of surgery to prevent scar formation, such application 
remains controversial.
Steroids may be considered as an important tre-
atment option for various diseases, mainly inflammatory 
ones that adversely affect the vocal folds.
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